Index of reports
> Cases with Death (92)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cytarabine where reactions include death. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 92 Next >>
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-08-15
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2, cyclic
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: 60 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-08-15
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Methotrexate
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Decadron
Dosage: 10 mg/m2, cyclic
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: 60 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Oncaspar
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-08-15
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Dosage: 60 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2, cyclic
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-08-15
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: 60 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Decadron
Dosage: 10 mg/m2, cyclic
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Oncaspar
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-08-15
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: 60 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2, cyclic
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-08-15
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Oncaspar
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Decadron
Dosage: 10 mg/m2, cyclic
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: 60 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-08-15
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Decadron
Dosage: 10 mg/m2, cyclic
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Oncaspar
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: 60 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in female
Reported by a physician from United States on 2012-07-26
Patient: female
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Temozolomide
Indication: Brain Neoplasm
Etoposide
Administration route: Oral
Velcade
Indication: Brain Neoplasm
Possible Cytarabine side effects in 50 year old female
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-06
Patient: 50 year old female
Reactions: Haemoptysis, Refractoriness To Platelet Transfusion, Petechiae, Pancytopenia, Febrile Neutropenia, Pyrexia, Alveolitis Allergic, Death, Panniculitis, Colitis, Thrombocytopenia, Laryngospasm, Klebsiella Sepsis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Immune Globulin NOS
Indication: Pancytopenia
Mitoxantrone
Dosage: 10 mg/m2 on d1-5; 2nd induction chemotherapy
Indication: Acute Myeloid Leukaemia
Idarubicin HCL
Dosage: 12 mg/m2 on d1-3; induction chemotherapy
Indication: Acute Myeloid Leukaemia
Cytarabine
Dosage: 100 mg/m2 on d1-7; induction chemotherapy
Indication: Acute Myeloid Leukaemia
Etoposide
Dosage: 100 mg/m2 on d1-5; 2nd induction chemotherapy
Indication: Acute Myeloid Leukaemia
Other drugs received by patient: Vercyte
Possible Cytarabine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Idarubicin HCL
Indication: Acute Lymphocytic Leukaemia
Prednisone TAB
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Mercaptopurine
Indication: Acute Lymphocytic Leukaemia
Elspar
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Elspar
Indication: Acute Lymphocytic Leukaemia
Prednisone
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Idarubicin HCL
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Mercaptopurine
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Mercaptopurine
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Prednisone TAB
Indication: Acute Lymphocytic Leukaemia
Elspar
Indication: Acute Leukaemia
Idarubicin HCL
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Dexamethasone
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-06-26
Patient:
Reactions: Death, Neoplasm Malignant, Burkitt's Lymphoma Recurrent, Myelodysplastic Syndrome, Burkitt's Leukaemia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Monoclonal Antibodies
Dosage: standard dose
Indication: Acute Lymphocytic Leukaemia
Monoclonal Antibodies
Dosage: standard dose
Indication: Burkitt's Lymphoma
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Dexamethasone
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Vincristine
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Burkitt's Lymphoma
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Unknown Medication
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-06-26
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Dexamethasone
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Cyclophosphamide
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Monoclonal Antibodies
Dosage: standard dose
Indication: Acute Lymphocytic Leukaemia
Monoclonal Antibodies
Dosage: standard dose
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Burkitt's Lymphoma
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: ALL Other Therapeutic Drugs
Possible Cytarabine side effects in
Reported by a physician from Germany on 2012-06-21
Patient:
Reactions: Alanine Aminotransferase Increased, Arrhythmia, Death, Neurotoxicity, Mucosal Inflammation, Lung Disorder, Aspartate Aminotransferase Increased, Cardiotoxicity, Cardiac Failure Congestive, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Granulocyte Colony Stimulating Factor
Dosage: induction 2; day 21-28
Indication: Acute Myeloid Leukaemia
Daunorubicin HCL
Dosage: induction 2; day 21-28
Indication: Acute Lymphocytic Leukaemia
Idarubicin HCL
Dosage: induction 1; day 1
Etoposide
Dosage: induction 1; day 1
Indication: Acute Lymphocytic Leukaemia
Cladribine
Dosage: between days 42-56; consolidation phase
Indication: Acute Lymphocytic Leukaemia
Cladribine
Dosage: between days 42-56; consolidation phase
Indication: Acute Myeloid Leukaemia
Cytarabine
Dosage: day 42-56 (0.5g/m2), consolidation phase
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: induction 2; high dose; days 21-28
Idarubicin HCL
Dosage: induction 1; day 1
Etoposide
Dosage: induction 1; day 1
Indication: Acute Myeloid Leukaemia
Idarubicin HCL
Dosage: day 42-56; consolidation phase
Indication: Acute Myeloid Leukaemia
Granulocyte Colony Stimulating Factor
Dosage: induction 2; day 21-28
Indication: Acute Lymphocytic Leukaemia
Daunorubicin HCL
Dosage: induction 2; day 21-28
Indication: Acute Myeloid Leukaemia
Cytarabine
Dosage: day 42-56 (0.5g/m2), consolidation phase
Indication: Acute Myeloid Leukaemia
Cytarabine
Dosage: induction 2; high dose; days 21-28
Idarubicin HCL
Dosage: day 42-56; consolidation phase
Indication: Acute Lymphocytic Leukaemia
Fludarabine Phosphate
Dosage: induction 2; day 21-28
Indication: Acute Myeloid Leukaemia
Cytarabine
Dosage: induction 1; day 1
Cytarabine
Dosage: induction 1; day 1
Mitoxantrone
Dosage: induction 2; day 21-28
Indication: Acute Lymphocytic Leukaemia
Mitoxantrone
Dosage: induction 2; day 21-28
Indication: Acute Myeloid Leukaemia
Fludarabine Phosphate
Dosage: induction 2; day 21-28
Indication: Acute Lymphocytic Leukaemia
Possible Cytarabine side effects in
Reported by a physician from Germany on 2012-06-18
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Cladribine
Dosage: between days 42-56; consolidation phase
Indication: Acute Myeloid Leukaemia
Cytarabine
Dosage: day 42-56 (0.5g/m2), consolidation phase
Cytarabine
Dosage: induction 1; day 1
Indication: Acute Myeloid Leukaemia
Idarubicin HCL
Dosage: day 42-56; consolidation phase
Indication: Acute Myeloid Leukaemia
Cytarabine
Dosage: induction 2; high dose; days 21-28
Etoposide
Dosage: induction 1; day 1
Indication: Acute Myeloid Leukaemia
Idarubicin HCL
Dosage: induction 1; day 1
Mitoxantrone
Dosage: induction 2; day 21-28
Indication: Acute Myeloid Leukaemia
Possible Cytarabine side effects in 26 year old male
Reported by a health professional (non-physician/pharmacist) from Spain on 2012-06-15
Patient: 26 year old male
Reactions: Death, non-Hodgkin's Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: unk
Indication: non-Hodgkin's Lymphoma
Fludara
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Clofarabine
Dosage: unk
Indication: non-Hodgkin's Lymphoma
Other drugs received by patient: Busulfan; Thiotepa
Possible Cytarabine side effects in 41 year old male
Reported by a health professional (non-physician/pharmacist) from Spain on 2012-06-15
Patient: 41 year old male
Reactions: Death, non-Hodgkin's Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Clofarabine
Dosage: unk
Indication: non-Hodgkin's Lymphoma
Fludara
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Cytarabine
Dosage: unk
Indication: non-Hodgkin's Lymphoma
Other drugs received by patient: Thiotepa; Busulfan
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-06-12
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Burkitt's Lymphoma
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Monoclonal Antibodies
Dosage: standard dose
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Burkitt's Lymphoma
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Burkitt's Lymphoma
Vincristine
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Burkitt's Lymphoma
Monoclonal Antibodies
Dosage: standard dose
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: ALL Other Therapeutic Drugs
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-06-12
Patient:
Reactions: Death, Burkitt's Lymphoma Recurrent, Neoplasm Malignant, Myelodysplastic Syndrome, Burkitt's Leukaemia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Monoclonal Antibodies
Dosage: standard dose
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Monoclonal Antibodies
Dosage: standard dose
Indication: Acute Lymphocytic Leukaemia
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Burkitt's Lymphoma
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Burkitt's Lymphoma
Vincristine
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Unknown Medication
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-06-12
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Chromosome Analysis Abnormal
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Dasatinib
Dosage: first 14 days of each of 8 cycles of alternating hypercvad
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Chronic Myeloid Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Chronic Myeloid Leukaemia
Doxorubicin Hydrochloride
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Dasatinib
Dosage: first 14 days of each of 8 cycles of alternating hypercvad
Administration route: Oral
Indication: Chronic Myeloid Leukaemia
Methotrexate
Indication: Chronic Myeloid Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Indication: Chronic Myeloid Leukaemia
Cyclophosphamide
Indication: Chronic Myeloid Leukaemia
Dexamethasone
Indication: Chronic Myeloid Leukaemia
Possible Cytarabine side effects in female
Reported by a physician from United States on 2012-06-06
Patient: female
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Indication: Brain Neoplasm
Temozolomide
Indication: Brain Neoplasm
Etoposide
Administration route: Oral
Indication: Brain Neoplasm
Velcade
Indication: Brain Neoplasm
Possible Cytarabine side effects in
Reported by a individual with unspecified qualification from Denmark on 2012-06-01
Patient:
Reactions: Neurotoxicity, Death, Sepsis, Haematotoxicity
Adverse event resulted in: death
Drug(s) suspected as cause:
Temozolomide
Indication: Central Nervous System Lymphoma
Dexamethasone
Indication: Central Nervous System Lymphoma
Ifosfamide
Indication: Central Nervous System Lymphoma
Vincristine
Indication: Central Nervous System Lymphoma
Mabthera
Indication: Central Nervous System Lymphoma
Cyclophosphamide
Indication: Central Nervous System Lymphoma
Cytarabine
Methotrexate
Indication: Central Nervous System Lymphoma
Cytarabine
Indication: Central Nervous System Lymphoma
Vindesine
Indication: Central Nervous System Lymphoma
Possible Cytarabine side effects in female
Reported by a physician from United Kingdom on 2012-05-22
Patient: female
Reactions: Death
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: unk
Indication: Acute Myeloid Leukaemia
Start date: 2012-05-03
Everolimus
Dosage: unk
Indication: Acute Myeloid Leukaemia
Start date: 2012-05-03
Possible Cytarabine side effects in 61 year old male
Reported by a physician from Greece on 2012-05-18
Patient: 61 year old male
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Methotrexate Sodium
Indication: Leukaemia
Cytarabine
Indication: Leukaemia
Doxorubicin HCL
Indication: Leukaemia
Possible Cytarabine side effects in 30 year old female
Reported by a physician from France on 2012-05-07
Patient: 30 year old female
Reactions: Bronchopulmonary Aspergillosis, Death, Acute Respiratory Distress Syndrome
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Evoltra
Indication: Acute Myeloid Leukaemia
Cytarabine
Indication: Acute Myeloid Leukaemia
Cyclophosphamide
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Start date: 2011-11-26
End date: 2011-11-30
Thymoglobulin
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Start date: 2011-11-26
End date: 2011-11-30
Cyclophosphamide
Indication: Acute Myeloid Leukaemia
Evoltra
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Start date: 2011-11-26
End date: 2011-11-30
Cytarabine
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Start date: 2011-11-26
End date: 2011-11-30
Thymoglobulin
Indication: Acute Myeloid Leukaemia
Possible Cytarabine side effects in 61 year old male
Reported by a physician from Greece on 2012-05-02
Patient: 61 year old male
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Methotrexate Sodium
Indication: Leukaemia
Doxorubicin HCL
Indication: Leukaemia
Cytarabine
Indication: Leukaemia
Possible Cytarabine side effects in 45 year old male
Reported by a health professional (non-physician/pharmacist) from Spain on 2012-04-30
Patient: 45 year old male
Reactions: Neurological Decompensation, Graft Versus Host Disease, Central Nervous System Lesion, Hemiparesis, Viith Nerve Paralysis, Iiird Nerve Disorder, Death, Myoclonus, Cranial Nerve Disorder, Progressive Multifocal Leukoencephalopathy, Asthenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclosporine
Dosage: 5 mg/kg, per day
Administration route: Oral
Indication: Graft Versus Host Disease
Tacrolimus
Dosage: 0.1 mg/kg, per day
Indication: Graft Versus Host Disease
Prednisone
Dosage: 2 mg/kg, per day
Administration route: Oral
Indication: Graft Versus Host Disease
Sirolimus
Indication: Graft Versus Host Disease
Cytarabine
Dosage: two more cycles
Fludarabine Phosphate
Dosage: two cycles
Indication: Acute Myeloid Leukaemia
Mycophenolate Mofetil
Dosage: 2 g, per day
Start date: 2009-12-01
Idarubicin HCL
Dosage: 12 mg/m2, per day for 3 days
Indication: Acute Myeloid Leukaemia
Idarubicin HCL
Dosage: two cycles
Cytarabine
Dosage: 200 mg/m2, per day for 7 days
Indication: Acute Myeloid Leukaemia
Start date: 2008-12-01
Fludarabine Phosphate
Dosage: 160 mg/m2, for conditioning
Indication: Bone Marrow Conditioning Regimen
Busulfan
Dosage: 12.8 mg/kg, unk
Indication: Bone Marrow Conditioning Regimen
Other drugs received by patient: Granulocyte Colony Stimulating Factor; Gemtuzumab Ozogamicin
Possible Cytarabine side effects in 45 year old male
Reported by a health professional (non-physician/pharmacist) from Spain on 2012-04-30
Patient: 45 year old male
Reactions: Neurological Decompensation, Graft Versus Host Disease, Central Nervous System Lesion, Hemiparesis, Iiird Nerve Disorder, Viith Nerve Paralysis, Myoclonus, Death, Cranial Nerve Disorder, Progressive Multifocal Leukoencephalopathy, Asthenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Mycophenolate Mofetil
Dosage: 2 g, per day
Start date: 2009-12-01
Cytarabine
Dosage: 200 mg/m2, per day for 7 days
Indication: Acute Myeloid Leukaemia
Start date: 2008-12-01
Cytarabine
Dosage: two more cycles
Idarubicin HCL
Dosage: two cycles
Fludarabine Phosphate
Dosage: 160 mg/m2, for conditioning
Indication: Bone Marrow Conditioning Regimen
Busulfan
Dosage: 12.8 mg/kg, unk
Indication: Bone Marrow Conditioning Regimen
Fludarabine Phosphate
Dosage: two cycles
Indication: Acute Myeloid Leukaemia
Cyclosporine
Dosage: 5 mg/kg, per day
Administration route: Oral
Indication: Graft Versus Host Disease
Idarubicin HCL
Dosage: 12 mg/m2, per day for 3 days
Indication: Acute Myeloid Leukaemia
Tacrolimus
Dosage: 0.1 mg/kg, per day
Indication: Graft Versus Host Disease
Prednisone
Dosage: 2 mg/kg, per day
Administration route: Oral
Indication: Graft Versus Host Disease
Sirolimus
Indication: Graft Versus Host Disease
Other drugs received by patient: Gemtuzumab Ozogamicin; Granulocyte Colony Stimulating Factor
Possible Cytarabine side effects in
Reported by a physician from United States on 2012-04-27
Patient:
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Vincristine
Indication: Burkitt's Lymphoma
Dexamethasone
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Rituximab
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Cyclophosphamide
Indication: Burkitt's Lymphoma
Page 1 Next >>
|